Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans

Vaccine

Volumn 28, Issue 23, 2010, Pages 3977-3989

  Tan, Tze Guan ^a,b   Mui, Ernest ^a,b   Cong, Hua ^a,b,c   Witola, William H ^a,b   Montpetit, Alexandre ^d   Muench, Stephen P ^e   Sidney, John ^f   Alexander, Jeff ^g   Sette, Alessandro ^f   Grigg, Michael E ^h   Maewal, Ajesh ⁱ   McLeod, Rima ^a,b  

^a THE UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c SHANDONG UNIVERSITY   (China)

^d Centre d'Innovation   (Canada)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^g Epimmune   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ Synthetic Biomolecules   (United States)

Author keywords

HLA Class 1 bound peptides; Toxoplasma gondii; Vaccine

Indexed keywords

AMINOPEPTIDASE; BACTERIAL PROTEIN; ENDOPLASMIC RETICULUM ASSOCIATED AMINOPEPTIDASE; EPITOPE; GAMMA INTERFERON; GRA3 PROTEIN; GRA6 PROTEIN; GRA7 PROTEIN; HISTIDINYLPROPYLGLYCYLSERYLVALYLASPARAGINYLGLUTAMYLPHENYLALANYLASPARTYLPHENYLALANINE; HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SAG1 PROTEIN; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONGENITAL TOXOPLASMOSIS; CONTROLLED STUDY; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IMMUNOGENETICS; IMMUNOGENICITY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TOXOPLASMOSIS;

ADJUVANTS, IMMUNOLOGIC; AMINOPEPTIDASES; ANIMALS; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MODELS, MOLECULAR; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TOXOPLASMA; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL;

EID: 77952545400     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.028     Document Type: Article

References (52)

1. Ajzenberg D., Banuls A.L., Su C., Dumetre A., Demar M., Carme B., et al. Genetic diversity, clonality and sexuality in Toxoplasma gondii. Int J Parasitol 34 (2004) 1185-1196
2. Ryning F.W., McLeod R., Maddox J.C., Hunt S., and Remington J.S. Probable transmission of Toxoplasma gondii by organ transplantation. Ann Intern Med 90 (1979) 47-49
3. Gazzinelli R.T., Hakim F.T., Hieny S., Shearer G.M., and Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 146 (1991) 286-292
4. Suzuki Y., Orellana M.A., Schreiber R.D., and Remington J.S. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240 (1988) 516-518
5. Brown C.R., and McLeod R. Class I MHC genes and CD8+ T cells determine cyst number in Toxoplasma gondii infection. J Immunol 145 (1990) 3438-3441
6. Brown C.R., Hunter C.A., Estes R.G., Beckmann E., Forman J., David C., et al. Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology 85 (1995) 419-428
7. Johnson J.J., Roberts C.W., Pope C., Roberts F., Kirisits M.J., Estes R., et al. In vitro correlates of Ld-restricted resistance to toxoplasmic encephalitis and their critical dependence on parasite strain. J Immunol 169 (2002) 966-973
8. McLeod R., Boyer K., Karrison T., Kasza K., Swisher C., Roizen N., et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis 42 (2006) 1383-1394
9. McLeod R., Kieffer F., Sautter M., Hosten T., and Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis?. Mem Inst Oswaldo Cruz 104 (2009) 320-344
10. McLeod R., Frenkel J.K., Estes R.G., Mack D.G., Eisenhauer P.B., and Gibori G. Subcutaneous and intestinal vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to peroral and congenital toxoplasma challenge. J Immunol 140 (1988) 1632-1637
11. Golkar M., Shokrgozar M.A., Rafati S., Musset K., Assmar M., Sadaie R., et al. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine 25 (2007) 4301-4311
12. Leyva R., Herion P., and Saavedra R. Genetic immunization with plasmid DNA coding for the ROP2 protein of Toxoplasma gondii. Parasitol Res 87 (2001) 70-79
13. Lourenco E.V., Bernardes E.S., Silva N.M., Mineo J.R., Panunto-Castelo A., and Roque-Barreira M.C. Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii. Microbes Infect 8 (2006) 1244-1251
14. Nielsen H.V., Lauemoller S.L., Christiansen L., Buus S., Fomsgaard A., and Petersen E. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect Immun 67 (1999) 6358-6363
15. Blanchard N., Gonzalez F., Schaeffer M., Joncker N.T., Cheng T., Shastri A.J., et al. Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum. Nat Immunol 9 (2008) 937-944
16. Corr M., Boyd L.F., Frankel S.R., Kozlowski S., Padlan E.A., and Margulies D.H. Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex. J Exp Med 176 (1992) 1681-1692
17. Sidney J., Peters B., Frahm N., Brander C., and Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 9 (2008) 1
18. Sette A., Sidney J., Livingston B.D., Dzuris J.L., Crimi C., Walker C.M., et al. Class I molecules with similar peptide-binding specificities are the result of both common ancestry and convergent evolution. Immunogenetics 54 (2003) 830-841
19. Caetano B.C., Bruna-Romero O., Fux B., Mendes E.A., Penido M.L., and Gazzinelli R.T. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice. Hum Gene Ther 17 (2006) 415-426
20. Frickel E.M., Sahoo N., Hopp J., Gubbels M.J., Craver M.P., Knoll L.J., et al. Parasite stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T cell epitopes. J Infect Dis 198 (2008) 1625-1633
21. Livingston B.D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K., et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 162 (1999) 3088-3095
22. Deliyannis G., Jackson D.C., Ede N.J., Zeng W., Hourdakis I., Sakabetis E., et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 76 (2002) 4212-4221
23. BenMohamed L., Krishnan R., Auge C., Primus J.F., and Diamond D.J. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106 (2002) 113-121
24. BenMohamed L., Wechsler S.L., and Nesburn A.B. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis 2 (2002) 425-431
25. Reed S.G., Bertholet S., Coler R.N., and Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 30 (2009) 23-32
26. Zeng W., Ghosh S., Lau Y.F., Brown L.E., and Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 169 (2002) 4905-4912
27. Ishioka G.Y., Fikes J., Hermanson G., Livingston B., Crimi C., Qin M., et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 162 (1999) 3915-3925
28. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 10 (2002) S32-S37
29. Sette A., and Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50 (1999) 201-212
30. Hammer G.E., Kanaseki T., and Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity 26 (2007) 397-406
31. Alexander J., Oseroff C., Sidney J., and Sette A. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes. Hum Immunol 64 (2003) 211-223
32. Kong J.T., Grigg M.E., Uyetake L., Parmley S., and Boothroyd J.C. Serotyping of Toxoplasma gondii infections in humans using synthetic peptides. J Infect Dis 187 (2003) 1484-1495
33. Mack D.G., Johnson J.J., Roberts F., Roberts C.W., Estes R.G., David C., et al. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 29 (1999) 1351-1358
34. Botten J., Alexander J., Pasquetto V., Sidney J., Barrowman P., Ting J., et al. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 80 (2006) 8351-8361
35. Nielsen M., Lundegaard C., Lund O., and Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57 (2005) 33-41
36. Kim S.K., Karasov A., and Boothroyd J.C. Bradyzoite-specific surface antigen SRS9 plays a role in maintaining Toxoplasma gondii persistence in the brain and in host control of parasite replication in the intestine. Infect Immun 75 (2007) 1626-1634
37. Jamieson S.E., de Roubaix L.A., Cortina-Borja M., Tan H.K., Mui E.J., Cordell H.J., et al. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One 3 (2008) e2285
38. Saeij J.P., Arrizabalaga G., and Boothroyd J.C. A cluster of four surface antigen genes specifically expressed in bradyzoites, SAG2CDXY, plays an important role in Toxoplasma gondii persistence. Infect Immun 76 (2008) 2402-2410
39. Sidney J., Assarsson E., Moore C., Ngo S., Pinilla C., Sette A., et al. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res 4 (2008) 2
40. Sidney J., Southwood S., Mann D.L., Fernandez-Vina M.A., Newman M.J., and Sette A. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 62 (2001) 1200-1216
41. Sidney J., Southwood S., Oseroff C., del Guercio M.F., Sette A., and Grey H.M. Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol (2001) [Chapter 18:Unit 18 3]
42. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
43. Gulukota K., Sidney J., Sette A., and DeLisi C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol 267 (1997) 1258-1267
44. Hourigan C.S., Harkiolaki M., Peterson N.A., Bell J.I., Jones E.Y., and O'Callaghan C.A. The structure of the human allo-ligand HLA-B*3501 in complex with a cytochrome p450 peptide: steric hindrance influences TCR allo-recognition. Eur J Immunol 36 (2006) 3288-3293
45. Speir J.A., Garcia K.C., Brunmark A., Degano M., Peterson P.A., Teyton L., et al. Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes. Immunity 8 (1998) 553-562
46. Cesbron-Delauw M.F., and Capron A. Excreted/secreted antigens of Toxoplasma gondii-their origin and role in the host-parasite interaction. Res Immunol 144 (1993) 41-44
47. Schild H., Deres K., Wiesmuller K.H., Jung G., and Rammensee H.G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol 21 (1991) 2649-2654
48. Tsunoda I., Sette A., Fujinami R.S., Oseroff C., Ruppert J., Dahlberg C., et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine 17 (1999) 675-685
49. Saveanu L., Carroll O., Lindo V., Del Val M., Lopez D., Lepelletier Y., et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 6 (2005) 689-697
50. Hammer G.E., Gonzalez F., Champsaur M., Cado D., and Shastri N. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 7 (2006) 103-112
51. Beghetto E., Nielsen H.V., Del Porto P., Buffolano W., Guglietta S., Felici F., et al. A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts. J Infect Dis 191 (2005) 637-645
52. Dubey J.P., Speer C.A., Shen S.K., Kwok O.C., and Blixt J.A. Oocyst-induced murine toxoplasmosis: life cycle, pathogenicity, and stage conversion in mice fed Toxoplasma gondii oocysts. J Parasitol 83 (1997) 870-882